Gastrointestinal stromal tumor cell lines - the mechanisms of chemosensitivity in vitro

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access


This research was aimed to study the sensitivity of gastrointestinal stromal tumors (GISTs) to chemotherapeutic drugs. We studied the chemosensitivity of GISTs by using several GIST cell lines. Cytotoxicity of chemotherapeutic drugs was assessed by colorometric MTS-assay. The expression level of DNA damage markers and repair proteins was assessed by immunoblotting. Apoptosis analysis was conducted by measuring the amount of hypodiploid cells by using a propidium iodide DNA staining procedure and flow cytometry analysis. We found that GISTs are sensitive to certain chemotherapeutic drugs - topoisomerase II inhibitors (etoposide and doxorubicine). DNA damage induction (in particular, DNA double-strand breaks formation) in GISTs induced cell apoptotic cell death despite the activation of DNA repair pathways. Of note, this effect was observed in imatinib-sensitive and resistant GIST cell lines, as well. We also found an increase accumulation phosphorylated form of histone 2A in GISTs after imatinib treatment. This effect was associated with the significant reduction of Rad51 recombinase expression, known as a key factor of homologous recombination. Taken together, this might explain the possible mechanisms of cell death in GISTs after targeted therapy. We found the chemosensitivity of GIST cell lines to some certain chemotherapeutic agents. Thus, the current point of view indicating about GISTs resistance to chemotherapy is needed to be re-evaluated.

Full Text

Restricted Access

About the authors

S. V Boichuk

Kazan State Medical University; University of Pittsburgh Cancer Institute

B. R Ramazanov

Kazan State Medical University

A. R Galembikova

Kazan State Medical University

I. G Mustafin

Kazan State Medical University

A. Duensing

University of Pittsburgh Cancer Institute


  1. Hirota S., Isozaki K., Moriyama Y. et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998; 279: 577-80.
  2. Demetri G.D., Mehren von M., Blanke C.D. et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N. Engl. J. Med. 2002; 347: 472-80.
  3. Verweij J., Casali P.G., Zalcberg J. et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004; 364: 1127-32.
  4. Gramza A.W., Corless C.L., Heinrich M.C. Resistance to tyrosine kinase inhibitors in gastrointestinal stromal tumors. Clin. Cancer Res. 2009; 15: 7510-8.
  5. Demetri G.D., Reichardt P., Kang Y-K. et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013; 38: 295-302.
  6. Boichuk S., Rausch J, Duensing A. New developments in management of gastrointestinal stromal tumors: regorafenib, the new player in the team. Gastrointestinal Cancer: Targets and Therapy 2014; 4: 1-10.
  7. Dematteo R.P., Heinrich M.C., El-Rifai W.M. et al. Clinical management of gastrointestinal stromal tumors: before and after STI-571. Hum. Pathol. 2002; 33: 466-77.
  8. Boichuk S. Unbiased compound screening identifies unexpected drug sensitivities and novel treatment options for gastrointestinal stromal tumors. Cancer Res. 2014; 74(4): 1200-13.
  9. Stucki M., Clapperton J.A., Mohammad D. et al. MDC1 directly binds phosphorylated histone H2AX to regulate cellular responses to DNA double-strand breaks. Cell 2005; 123: 1213-26.
  10. Wu D., Ingram A., Lahti J.H. et al. Apoptotic release of histones from nucleosomes. J. Biol. Chem. 2002; 277: 12001-8.
  11. Liu Y., Tseng M., Perdreau S.A. et al. Histone H2AX is a mediator of gastrointestinal stromal tumor cell apoptosis following treatment with imatinib mesylate. Cancer Res. 2007; 67: 2685-92.
  12. Bauer S., Parry J.A., Muhlenberg T. et al. Proapoptotic activity of bortezomib in gastrointestinal stromal tumor cells. Cancer Res. 2010; 70: 150-9.
  13. Maurel J., Martins A.S., Poveda A. et al. Imatinib plus low-dose doxorubicin in patients with advanced gastrointestinal stromal tumors refractory to high-dose imatinib. Cancer 2010; 116: 3692-70.

Copyright (c) 2014 Eco-Vector

СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: ПИ № ФС 77 - 85657 от 21.07.2023 от 11.03.2014.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies